U.S. Markets close in 6 hrs 17 mins

# Don't Sell Neogen Corporation (NASDAQ:NEOG) Before You Read This

The goal of this article is to teach you how to use price to earnings ratios (P/E ratios). We'll apply a basic P/E ratio analysis to Neogen Corporation's (NASDAQ:NEOG), to help you decide if the stock is worth further research. Looking at earnings over the last twelve months, Neogen has a P/E ratio of 62.15. That corresponds to an earnings yield of approximately 1.6%.

See our latest analysis for Neogen

### How Do You Calculate A P/E Ratio?

The formula for price to earnings is:

Price to Earnings Ratio = Price per Share Ã· Earnings per Share (EPS)

Or for Neogen:

P/E of 62.15 = USD71.28 Ã· USD1.15 (Based on the trailing twelve months to November 2019.)

### Is A High P/E Ratio Good?

The higher the P/E ratio, the higher the price tag of a business, relative to its trailing earnings. That is not a good or a bad thing per se, but a high P/E does imply buyers are optimistic about the future.

### How Does Neogen's P/E Ratio Compare To Its Peers?

The P/E ratio essentially measures market expectations of a company. The image below shows that Neogen has a higher P/E than the average (47.6) P/E for companies in the medical equipment industry.

Its relatively high P/E ratio indicates that Neogen shareholders think it will perform better than other companies in its industry classification. Clearly the market expects growth, but it isn't guaranteed. So investors should delve deeper. I like to check if company insiders have been buying or selling.

### How Growth Rates Impact P/E Ratios

Probably the most important factor in determining what P/E a company trades on is the earnings growth. That's because companies that grow earnings per share quickly will rapidly increase the 'E' in the equation. That means unless the share price increases, the P/E will reduce in a few years. Then, a lower P/E should attract more buyers, pushing the share price up.

Neogen shrunk earnings per share by 9.3% last year. But it has grown its earnings per share by 13% per year over the last five years.

### Don't Forget: The P/E Does Not Account For Debt or Bank Deposits

One drawback of using a P/E ratio is that it considers market capitalization, but not the balance sheet. Thus, the metric does not reflect cash or debt held by the company. Hypothetically, a company could reduce its future P/E ratio by spending its cash (or taking on debt) to achieve higher earnings.

Such expenditure might be good or bad, in the long term, but the point here is that the balance sheet is not reflected by this ratio.

### Neogen's Balance Sheet

Since Neogen holds net cash of US\$314m, it can spend on growth, justifying a higher P/E ratio than otherwise.

### The Verdict On Neogen's P/E Ratio

Neogen's P/E is 62.2 which suggests the market is more focussed on the future opportunity rather than the current level of earnings. The recent drop in earnings per share might keep value investors away, but the net cash position means the company has time to improve: and the high P/E suggests the market thinks it will.

Investors have an opportunity when market expectations about a stock are wrong. People often underestimate remarkable growth -- so investors can make money when fast growth is not fully appreciated. So this free visualization of the analyst consensus on future earnings could help you make the right decision about whether to buy, sell, or hold.

Of course you might be able to find a better stock than Neogen. So you may wish to see this free collection of other companies that have grown earnings strongly.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.